Riboxx, CNBG unite in collaboration

A research collaboration has been announced between Riboxx Pharmaceuticals GmbH and China National Biotec Group Co. Ltd. to evaluate Riboxxim, Riboxx’s TLR3 agonist, with an antigen from CNBG against an undisclosed infectious disease target

Written byJeffrey Bouley

| 1 min read

To continue reading this article, subscribe for FREE to

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Jeffrey Bouley
This person does not yet have a bio.View Full Profile

Here are some related topics that may interest you:

Internal Medicine

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Sponsored

Shaping Science graphic featuring the question “How can labs become truly sustainable?” and a photo of James Connelly, Chief Executive Officer of My Green Lab.

How can labs become truly sustainable?

Creating more sustainable laboratories depends on practical changes that strengthen scientific performance while reducing environmental impact.

A gloved laboratory technician selects a labeled blood sample tube from a rack containing multiple color-coded collection tubes.

Technology Guide: Sample preparation for modern analytical workflows

Analytical performance begins long before a sample reaches the instrument, making sample preparation one of the most important determinants of data quality.

Technology Guides

Gloved researcher transferring liquid into a microplate using a multichannel pipette.

A practical guide to better pipetting

Discover practical strategies to improve pipetting accuracy, reproducibility, ergonomics, and instrument performance across diverse laboratory workflows.